These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 29277758)
21. PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features. Raze T; Lapouble E; Lacour B; Guissou S; Defachelles AS; Gaspar N; Delattre O; Pierron G; Desandes E Pediatr Blood Cancer; 2023 Apr; 70(4):e30228. PubMed ID: 36722003 [TBL] [Abstract][Full Text] [Related]
22. Prognostic value of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis. Kubo T; Shimose S; Fujimori J; Furuta T; Ochi M Crit Rev Oncol Hematol; 2015 Oct; 96(1):46-53. PubMed ID: 26008753 [TBL] [Abstract][Full Text] [Related]
23. Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Barr FG; Duan F; Smith LM; Gustafson D; Pitts M; Hammond S; Gastier-Foster JM Genes Chromosomes Cancer; 2009 Aug; 48(8):661-72. PubMed ID: 19422036 [TBL] [Abstract][Full Text] [Related]
24. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. Gryder BE; Yohe ME; Chou HC; Zhang X; Marques J; Wachtel M; Schaefer B; Sen N; Song Y; Gualtieri A; Pomella S; Rota R; Cleveland A; Wen X; Sindiri S; Wei JS; Barr FG; Das S; Andresson T; Guha R; Lal-Nag M; Ferrer M; Shern JF; Zhao K; Thomas CJ; Khan J Cancer Discov; 2017 Aug; 7(8):884-899. PubMed ID: 28446439 [TBL] [Abstract][Full Text] [Related]
25. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma. Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014 [TBL] [Abstract][Full Text] [Related]
27. Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements. Vicente-García C; Villarejo-Balcells B; Irastorza-Azcárate I; Naranjo S; Acemel RD; Tena JJ; Rigby PWJ; Devos DP; Gómez-Skarmeta JL; Carvajal JJ Genome Biol; 2017 Jun; 18(1):106. PubMed ID: 28615069 [TBL] [Abstract][Full Text] [Related]
28. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Linardic CM; Naini S; Herndon JE; Kesserwan C; Qualman SJ; Counter CM Cancer Res; 2007 Jul; 67(14):6691-9. PubMed ID: 17638879 [TBL] [Abstract][Full Text] [Related]
30. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas. Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794 [TBL] [Abstract][Full Text] [Related]